Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

60%

3 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3

2(40.0%)

N/A

2(40.0%)

Phase 4

1(20.0%)

5Total

Phase 3(2)

N/A(2)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT07101419Not ApplicableNot Yet Recruiting

Speed of Lung Inflation During Ventilation of Extremely Preterm Infants

Role: collaborator

NCT01906853Phase 3Completed

Melbourne Infant Study - Bacille Calmette Guérin (BCG) for Allergy & Infection Reduction

Role: collaborator

NCT02140580Phase 4Unknown

OPTIMIST-A Trial: Minimally-invasive Surfactant Therapy in Preterm Infants 25-28 Weeks Gestation on CPAP

Role: collaborator

NCT02444611Not ApplicableCompleted

A Trial Investigating the Influence of BCG and Hepatitis B Immunisation at Birth on Neonatal Immune Responses: The Early Life Vaccines and Immunity Study

Role: collaborator

NCT00431418Phase 3Completed

The Effect of Sildenafil in Preterm Infants With Evolving Chronic Lung Disease

Role: lead

All 5 trials loaded